SecBot SecBot
8-K ·Filed Nov 2, 2026

INO

INOVIO PHARMACEUTICALS, INC.
BULLISH
Impact 6/10
Horizonmonths Processed14d 20h ago SEC0001193125-26-442648
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

Monitor the confirmatory study protocol submission by end of 2026 and finalization by mid-2027, as continued approval depends on it. Track initial commercial uptake and payer coverage in the first two quarters post-launch (Q1-Q2 2027). The concentrated prescriber base (~400 laryngologists) and Syneos Health field deployment partner suggest a focused commercial execution risk.

DirectionBullish
Confidencehigh
Horizonmonths

Drug in focus

INO drug pipeline →

VOCERYQ

● Neutral Named in this 8-K
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.
Next catalyst
None dated

What to watchWith the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.89
T+0 close · Nov 2, 2026 · via day close
Latest settled
−20.11%
T+5 · $1.51 · next T+20 in 14d
Vs SPY
−20.18%
α at T+5
Latest observation
−20.09%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $1.89entry
  2. T+1 · 14d ago −12.17%α −12.47% · $1.66
  3. T+5 · 8d ago −20.11%α −20.18% · $1.51
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inovio Pharmaceuticals announced FDA accelerated approval of VOCERYQ (INO-3107), the first U.S. FDA-approved DNA medicine, to reduce surgery frequency in adults with Recurrent Respiratory Papillomatosis (RRP). The approval is based on a 32-patient Phase 1/2 study where 27% of evaluable patients required no surgical intervention for 12 months post-treatment. The company expects to begin shipping in approximately 60 days with full commercial launch in Q1 2027, but continued approval is contingent on a confirmatory study with a protocol due by end of 2026.

Key Facts

  • FDA granted accelerated approval for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce the frequency of surgery in adults with RRP.
  • Approval based on a Phase 1/2 study (RRP-001) in 32 patients; 26 patients in the efficacy population had a median of 4.5 surgeries in the 12 months prior to treatment.
  • 7 out of 26 patients (27%, 95% CI: 12-48%) demonstrated a complete response, defined as no surgical excision of papillomas after 12 months of follow-up.
  • VOCERYQ is the first U.S. FDA-approved DNA medicine, validating Inovio's platform technology.
  • Company expects to make VOCERYQ available to order and ship in approximately 60 days, with full field deployment in Q1 2027.
  • Continued approval is contingent on verification of clinical benefit in a confirmatory study; FDA requires a draft protocol by end of 2026 with final protocol alignment by mid-2027.
  • Inovio estimates a prevalent population of at least 25,000 RRP patients in the United States.
  • VOCERYQ was approved in combination with the CELLECTRA 5PSP delivery device.

Financial Impact

First commercial product for Inovio, targeting a U.S. prevalent population of at least 25,000 RRP patients. No revenue or pricing data disclosed in the filing.

revenue

Risk Factors

  • Continued approval is contingent on a confirmatory study; failure to demonstrate clinical benefit could lead to withdrawal of approval.
  • Commercial execution risk: first product launch for Inovio, relying on Syneos Health for field deployment.
  • Small study size (N=32) and open-label design may limit the strength of efficacy data.
  • No pricing or revenue guidance provided; profitability timeline uncertain.
  • Company has an $80M market cap with no prior product revenue, raising financing risk for commercial scale-up and confirmatory study costs.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-442648
Document: d150457dex992.htm0001193125-26-442648
Document: d150457dex991.htm0001193125-26-442648
Document: 0001193125-26-442648-index-headers.html0001193125-26-442648
Document: 0001193125-26-442648-index.html0001193125-26-442648
Document: 0001193125-26-442648.txt0001193125-26-442648

Track record

20 reports on INO

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
  4. Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
  5. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  6. Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  7. Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  8. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  9. Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  10. Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026